Donor-made virus-fighting T cells for hard-to-treat viral infections
Tests virus-fighting T cells from donors in adults with stubborn viral infections.
Key facts
- Who runs it
- Columbia University
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- R-MVST Cells for Treatment of Viral Infections
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 36 people, planned
- Started
- 3 May 2022
- Expected to end
- Jun 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Rapidly generated virus specific T (R-MVST) cells
- Record updated
- 10 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had a stem cell transplant or a solid organ transplant. They must have an EBV, CMV, adenovirus or BK virus infection that did not respond well enough to standard treatment.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- The virus has become active again or causes disease in organs or the whole body. At least one infection must be refractory, meaning it keeps coming back or involves more than one virus and needed treatment.
- Earlier treatment
- Standard treatment for the virus did not work well enough. People cannot join if they had ATG, Alemtuzumab (Campath) or similar antibodies, extracorporeal photopheresis or donor lymphocyte infusion in the last 28 days. They also cannot join if they had methotrexate or similar drugs in the last 7 days, checkpoint inhibitors within 3 drug half-lives, or a study drug within 14 days.
- Biomarker or test result
- Virus found by PCR test (EBV, CMV, ADV or BK virus).
Main reasons for not taking part
- Other uncontrolled infections besides CMV, EBV, ADV or BK
- Steroids at ≥ 0.5mg/kg prednisone or equivalent
- Graft-versus-host disease grade 2 or higher, or biopsy-proven acute rejection of a transplanted organ
- Active, uncontrolled return of cancer
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 18 criteriaShow less
Other criteria
- Recipient Inclusion Criteria:
- Men and women ages 18 years or older of all ethnic groups will be eligible for the treatment
- Patients with history of HCT or SOT who demonstrate evidence of viral reactivation and/or infection manifesting as end-organ or systemic disease due to one or more of the following viruses: EBV, CMV, ADV or BK virus and suboptimal response to the standard of care therapy
- Recurrent or Multiple Viral Infection. RVI defined as occurrence of more than one episode of reactivation that required intervention or symptomatic disease in recipient of allogeneic HCT that required standard of care treatment. MVI defined as more than one virus reactivating (defined by PCR positivity) or causing symptomatic systemic or end-organ disease. At least one of those viral reactivations required standard of care intervention. No standard of care therapy is defined for ADV and BK. Patients with multiple infections/reactivations will be eligible as long as at least one of those viral infections meet the criterium of "refractory"; Recipient Exclusion Criteria:
- Patients with other uncontrolled infections, except for CMV, EBV, ADV or BK. For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to the day of infusion. For fungal infections, patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to R-MVST infusion. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection
- Patients who receive corticosteroids at ≥ 0.5mg/kg prednisone or equivalent
- Patients who received anti-thymocyte globulin (ATG, Alemtuzumab (Campath), or other T-Cell immunosupressive monoclonal antibodies in the last 28 days
- Patients who received methotrexate, or other antimetabolite-type immunosuppressants that are toxic to proliferating T cells in the last 7 days
- Patients who received extracorporeal photopheresis within the last 28 days
- Patients who received checkpoint inhibitor agents (e.g., nivolumab, pembrolizumab, ipilimumab) within 3 drug half-lives of the most recent dose to the infusion of R-MVST
- Received donor lymphocyte infusion in last 28 days
- Evidence of GVHD ≥ grade 2
- Evidence of biopsy-proven acute rejection in SOT recipients
- Active and uncontrolled relapse of malignancy
- Patients who are pregnant, or breastfeeding
- Female of childbearing potential, or male with a female partner of childbearing potential, unwilling to use a highly effective method of contraception
- Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Patients who have received investigational (IND) product within 14 days of infusion of the the R-MVST cells; Donor inclusion and exclusion criteria will be followed as per the most current BMT SOP (Donor selection, Donor evaluation and Donor Deferral)
Where in United States
- Columbia University Irving Medical CenterNew York, United StatesContact: Pawel Muranski, MDTaking people
About the trial
What the trial wants to find out
The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. R-MVST cells will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available. The investigator will closely monitor the recipients for potential toxicities including graft-versus-host disease (GVHD) post-infusion.
Read full original descriptionShow less
Secondary objectives are to determine the effect of R-MVST infusion on viral load, possible recovery of antiviral immunity post-infusion and for evidence of clinical responses and overall survival. Recipients will be monitored for secondary graft failure at day 28 post R-MVST infusion.
The 2 groups in the trial
- Group A: Allogenic Stem Cell Transplant Recipient (SCT)Treatment being tested
Dose levels selected for Group A are based on previous experience with VST cells in HCT recipients and are lower than in Group B (SOT recipients), as donor-derived R-MVST cells are more likely to persist in recipients of HCT from the same donors. Thus, there is theoretically a higher risk for development of GVHD in this subset of patients. Each group will undergo independent dose escalation. Subjects will receive a single dose of R-MVST Cells, and followed for toxicity and GVHD for 28 days days after infusion. Up to two additional doses may be administered, minimum of 28 days apart if cohort safety is established and reinfusion criteria are met. A new 28-day safety-monitoring period will ensue for each additional infusion. Subjects will be followed for possible virological and clinical responses for up to 1 year after the initial R-MVST infusion.
Treatment: Rapidly generated virus specific T (R-MVST) cells
- Group B: Solid organ transplant recipients (SOT)Treatment being tested
In SOT recipients, the study will use higher doses of R-MVST cells, as the infused anti-viral T cells are less likely to persist long-term and cause GVHD, based on the safety profile of PyVST cells used for therapy of PML in non-HCT subjects. Subjects will receive a single dose of R-MVST Cells, and followed for toxicity and GVHD for 28 days days after infusion. Up to two additional doses may be administered, minimum of 28 days apart if cohort safety is established and reinfusion criteria are met. A new 28-day safety-monitoring period will ensue for each additional infusion. Subjects will be followed for possible virological and clinical responses for up to 1 year after the initial R-MVST infusion.
Treatment: Rapidly generated virus specific T (R-MVST) cells
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase I Study of Adoptive Immunotherapy of Refractory Viral Infection With ex Vivo Expanded Rapidly Generated Virus Specific T (R-MVST) Cells
- Plain-language title
- Donor-made virus-fighting T cells for hard-to-treat viral infectionsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 10 June 2026